Magid Abou-Gharbia is a Laura H. Carnell Professor of Pharmaceutical Sciences at Temple University’s School of Pharmacy, he joined Temple University in 2008 following his 26-year tenure as a medicinal chemistry researcher and leader in the pharmaceutical industry, where he rose through the ranks to ultimately become senior vice president for Chemical and Screening Sciences at Wyeth Research (now part of Pfizer). He led teams that delivered numerous new chemical entities into clinical evaluation and identified innovative agents benefiting millions of patients worldwide. In 2008, he transitioned to academia, joining the Temple University School of Pharmacy. Under his leadership, the Moulder Center identified novel drug candidates for the treatments for cocaine and alcohol addiction, metabolic disorders, cancer, and lysosomal storage diseases, which led to the formation of four startup biotech companies based on licensing of the center's intellectual property to external companies. He has held some leadership positions since joining Temple. He served as the School of Pharmacy’s associate dean for research (2008-2019) and the director of the Moulder Center for Drug Discovery Research (2008-2020). In recognition of his contributions and successes, he was named a Laura H. Carnell Professor in 2013 and received a Temple University Outstanding Service Award in 2022.
Magid Abou-Gharbia is a Laura H. Carnell Professor of Pharmaceutical Sciences at Temple University’s School of Pharmacy, he joined Temple University in 2008 following his 26-year tenure as a medicinal chemistry researcher and leader in the pharmaceutical industry, where he rose through the ranks to ultimately become senior vice president for Chemical and Screening Sciences at Wyeth Research (now part of Pfizer). He led teams that delivered numerous new chemical entities into clinical evaluation and identified innovative agents benefiting millions of patients worldwide. In 2008, he transitioned to academia, joining the Temple University School of Pharmacy. Under his leadership, the Moulder Center identified novel drug candidates for the treatments for cocaine and alcohol addiction, metabolic disorders, cancer, and lysosomal storage diseases, which led to the formation of four startup biotech companies based on licensing of the center's intellectual property to external companies. He has held some leadership positions since joining Temple. He served as the School of Pharmacy’s associate dean for research (2008-2019) and the director of the Moulder Center for Drug Discovery Research (2008-2020). In recognition of his contributions and successes, he was named a Laura H. Carnell Professor in 2013 and received a Temple University Outstanding Service Award in 2022.